↓ Skip to main content

Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

Overview of attention for article published in BMC Musculoskeletal Disorders, July 2011
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

patent
3 patents

Citations

dimensions_citation
130 Dimensions

Readers on

mendeley
129 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study
Published in
BMC Musculoskeletal Disorders, July 2011
DOI 10.1186/1471-2474-12-153
Pubmed ID
Authors

Rieke Alten, Juan Gomez-Reino, Patrick Durez, Andre Beaulieu, Anthony Sebba, Gerhard Krammer, Ralph Preiss, Udayasankar Arulmani, Albert Widmer, Xavier Gitton, Herbert Kellner

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 129 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
United States 1 <1%
Denmark 1 <1%
Ireland 1 <1%
Unknown 125 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 27 21%
Student > Master 15 12%
Student > Bachelor 14 11%
Researcher 12 9%
Student > Doctoral Student 11 9%
Other 29 22%
Unknown 21 16%
Readers by discipline Count As %
Medicine and Dentistry 50 39%
Agricultural and Biological Sciences 12 9%
Pharmacology, Toxicology and Pharmaceutical Science 10 8%
Biochemistry, Genetics and Molecular Biology 8 6%
Immunology and Microbiology 7 5%
Other 20 16%
Unknown 22 17%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 May 2022.
All research outputs
#7,656,056
of 23,308,124 outputs
Outputs from BMC Musculoskeletal Disorders
#1,557
of 4,132 outputs
Outputs of similar age
#42,301
of 117,591 outputs
Outputs of similar age from BMC Musculoskeletal Disorders
#19
of 47 outputs
Altmetric has tracked 23,308,124 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,132 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 117,591 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.